Focus on targets and cancer types with high high global unmet needs and commercial value.

Identification of promising targets for extrinsic factors (innate immunity) and intrinsic factors (RAS).

Establishing innovative drug pipelines with potential synergy with ADC.

Establish new modality platforms (TPD, ADC payloads) and expand the pipeline.